Compare Stryker Corporation (SYK) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs US Bancorp — how do they compare? Stryker Corporation trades at $319.04 (market cap $122.35B), while US Bancorp trades at $63.7 (market cap $98.36B). The key difference: Stryker Corporation is the larger of the two by market cap, and US Bancorp pays the higher dividend (3.29%). Which is the better fit depends on your goals.
| SYK | USB | |
|---|---|---|
Market Cap | $122.35B | $98.36B |
Sector | Technology | Financials |
52-Week High | $403.53 | $64.01 |
52-Week Low | $282.58 | $43.94 |
Enterprise Value | $134.10B | — |
Dividend Yield | 1% | 3.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $319.14, down 0.23% with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust margins. Recent news highlights Mako RPS launch expansion in robotic surgery, while Q1 2026 earnings missed expectations due to a temporary cyber disruption, though full-year guidance remains unchanged.
Outlook remains positive with 74% analyst buy ratings and a $388.44 consensus price target implying 22% upside. Key risks include competitive pressures and execution challenges from recent cybersecurity issues. The stock presents a growth opportunity in med-tech innovation, trading below historical valuation multiples with healthy cash flow generation.
U.S. Bancorp (USB) trades at $63.71, up 0.9% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with three consecutive quarterly EPS beats, a P/E of 12.6, and a net income margin of 27.61%. Recent Q2 2026 results highlighted record revenue driven by loan growth and fee income, with the company raising its full-year revenue outlook to 7%-9% growth. Analyst consensus is a Buy with a $70.17 price target, indicating 10% upside potential.
The outlook for USB is positive, supported by earnings momentum, dividend yield near 3%, and institutional optimism. Key risks include rising debt-to-asset ratios, potential credit quality deterioration, and macroeconomic sensitivity. Investors should weigh the stock's attractive valuation against sector-wide interest rate and regulatory uncertainties for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
